Healthcare Industry News: C.R. Bard
News Release - May 21, 2012
AngioDynamics Appoints Experienced Industry Executive as Chief Technology OfficerALBANY, N.Y., May 21, 2012 -- (Healthcare Sales & Marketing Network) -- AngioDynamics (Nasdaq:ANGO ), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of George W. Bourne as Senior Vice President and Chief Technology Officer, effective immediately. He joins the Company's executive leadership team reporting to President and CEO Joseph M. DeVivo.
Mr. Bourne served as Senior Vice President of R&D and Clinical Affairs for Navilyst Medical from its formation in early 2008 until November 2011. His tenure was defined by focused portfolio development and the commercialization of new products. Most recently, Mr. Bourne served as VP of R&D at Hologic. Previously, he spent 10 years at Boston Scientific as Vice President, R&D, of the Urology, Meditech and Oncology business units and then as Group Vice President, R&D, for the endosurgery business group. Mr. Bourne, who earned his Bachelor of Science in Biological Science and Master of Science in Plastics Engineering from the University of Lowell, in addition to his MBA from Rivier College in Nashua, N.H., also served in leadership positions at Baxter Healthcare, Allegiance Healthcare and C.R. Bard.
"George is a world-class engineer whose commitment to operational excellence has led him to establish and manage high-performance medical device R&D organizations," Mr. DeVivo said. "His extensive knowledge of Navilyst Medical's technology, pipeline and organization, combined with 25 years of experience in developing products in global medical device companies, make George the ideal fit for this important executive role. We welcome him to our team."
"The combination of AngioDynamics and Navilyst will create a more comprehensive and competitive portfolio of products differentiated by advanced technologies," Mr. Bourne said. "I look forward to working with Joseph DeVivo and his team to expand our product offering and drive growth."
AngioDynamics expects to complete the acquisition of Navilyst Medical on May 22, 2012. The acquisition will significantly expand AngioDynamics' scale, doubling its share of the vascular access market, while building critical mass in the peripheral vascular market.
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2011, and AngioDynamics' Forms 10-Q for the quarterly periods ended November 30, 2011, and February 29, 2012. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.